keyword
MENU ▼
Read by QxMD icon Read
search

vedolizumab crohn's

keyword
https://www.readbyqxmd.com/read/28204866/vedolizumab-treatment-for-immune-checkpoint-inhibitor-induced-enterocolitis
#1
Viktoria Bergqvist, Erik Hertervig, Peter Gedeon, Marija Kopljar, Håkan Griph, Sara Kinhult, Ana Carneiro, Jan Marsal
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy...
February 15, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#2
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
February 7, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28175096/p445-perioperative-use-of-vedolizumab-seems-not-associated-with-short-term-postoperative-infectious-complications-in-patients-with-crohn-s-disease-undergoing-right-hemicolectomy-with-ileocolonic-anastomosis
#3
N Schils, A De Buck van Overstraeten, S Vermeire, G Van Assche, A Wolthuis, A D'Hoore, M Ferrante
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175093/p501-baseline-characteristics-of-crohn-s-disease-patients-in-the-vedolizumab-pass-study-a-cohort-study-assessing-the-safety-and-effectiveness-of-vedolizumab-compared-to-other-biologic-agents-02
#4
C A Siegel, G Lichtenstein, B Siegmund, J D Lewis, D Wolf, E Louis, S Sebastian, X Hebuterne, A Bell, C Söderman, S Schubert, R Atreya, S Polyak, S Hoque, A Krummenerl, B Bokemeyer, T Krummenerl, S Shulmann, P Karlén, B Moum, P Dolin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172955/p447-vedolizumab-induces-significantly-higher-endoscopic-remission-rates-at-week-16-in-ulcerative-colitis-as-compared-to-crohn-s-disease
#5
R W M Pauwels, A C De Vries, C J Van der Woude
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172925/p391-differential-use-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-real-life-results-from-2-tertiary-referral-centres-in-the-united-kingdom
#6
N Kamperidis, A Cavazza, M Wahed, N Arebi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172887/p416-real-world-data-on-the-effectiveness-and-safety-of-vedolizumab-in-the-treatment-of-crohn-s-disease-and-ulcerative-colitis-the-edinburgh-experience
#7
N Plevris, T A Manship, A Deekae, G R Jones, C L Noble, J Satsangi, A G Shand, I D Arnott, C W Lees
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172706/dop021-long-term-effectiveness-and-safety-of-vedolizumab-in-patients-with-crohn-s-disease-5-year-cumulative-exposure-of-gemini-2-completers-rolling-into-the-gemini-open-label-extension-study
#8
S Vermeire, E V Loftus, J-F Colombel, B Feagan, W Sandborn, B Sands, S Danese, G D'Haens, A Kaser, R Panaccione, D Rubin, I Shafran, S O'Byrne, P Geransar, A Previtali, J M Khalid, A Kaviya
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172674/p531-discontinuation-of-corticosteroids-among-crohn-s-disease-patients-treated-with-vedolizumab-in-the-united-states
#9
H Patel, B Chastek, K D Null, D Demuth
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172630/dop019-effect-of-vedolizumab-treatment-on-extraintestinal-manifestations-in-patients-with-crohn-s-disease-a%C3%A2-gemini-2-post-hoc-analysis
#10
B G Feagan, W J Sandborn, J-F Colombel, S O'Byrne, J M Khalid, N Brayshaw, P Geransar, D T Rubin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172459/p305-indirect-comparison-of-two-novel-biologics-for-the-treatment-of-crohn-s-disease-network-meta-analysis-of-ustekinumab-vs-vedolizumab
#11
G Hather, R Curtis, K Minda, I A Zouraq, J M Khalid
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172422/dop020-higher-vedolizumab-levels-are-associated-with-deep-remission-in-patients-with-crohn-s-disease-and-ulcerative-colitis-on-maintenance-therapy-with-vedolizumab
#12
A Yarur, A Bruss, A Jain, V Kondragunta, K Hester, T Luna, D Agrawal, A Patel, C Fox, S Werner, S Naik, D Stein
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172395/op020-recent-anti-tnf-exposure-predicts-lower-vedolizumab-trough-concentrations-in-patients-with-crohn-s-disease
#13
A Gils, E Dreesen, G Compernolle, M Peeters, E Brouwers, S Tops, V Ballet, M Noman, M Ferrante, G Van Assche, S Vermeire
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28169436/vedolizumab-exposure-in-pregnancy-outcomes-from-clinical-studies-in-inflammatory-bowel-disease
#14
U Mahadevan, S Vermeire, K Lasch, B Abhyankar, F Bhayat, A Blake, M Dubinsky
BACKGROUND: Vedolizumab is a gut-selective immunoglobulin G1 monoclonal antibody to α4 β7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Prospective clinical studies of vedolizumab in pregnancy have not been conducted; therefore, existing safety data of vedolizumab in pregnancy were examined. AIM: To assess pregnancy outcomes in females and partners of males who received vedolizumab. METHODS: All pregnancy data collected during the clinical programme (from 14 May 2007 to 27 June 2013) and in the post-marketing setting (to 19 November 2015) were analysed...
February 7, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28161290/safety-of-treatments-for-inflammatory-bowel-disease-clinical-practice-guidelines-of-the-italian-group-for-the-study-of-inflammatory-bowel-disease-ig-ibd
#15
Livia Biancone, Vito Annese, Sandro Ardizzone, Alessandro Armuzzi, Emma Calabrese, Flavio Caprioli, Fabiana Castiglione, Michele Comberlato, Mario Cottone, Silvio Danese, Marco Daperno, Renata D'Incà, Giuseppe Frieri, Walter Fries, Paolo Gionchetti, Anna Kohn, Giovanni Latella, Monica Milla, Ambrogio Orlando, Claudio Papi, Carmelina Petruzziello, Gabriele Riegler, Fernando Rizzello, Simone Saibeni, Maria Lia Scribano, Maurizio Vecchi, Piero Vernia, Gianmichele Meucci
Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs...
January 17, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28147349/leukocyte-anti-trafficking-strategies-current-status-and-future-directions
#16
REVIEW
Bruce E Sands
BACKGROUND: In inflammatory bowel diseases (IBD), a pivotal step in the initiation and perpetuation of mucosal inflammation entails the recruitment of inflammatory leukocytes to the gut. Understanding the carefully coordinated series of molecular events that culminate in the recruitment of leukocytes to the gut has resulted in novel interventions with new capabilities in treating both Crohn's disease and ulcerative colitis. Key Messages: Natalizumab, an anti-α4 integrin antibody, was the first agent to demonstrate the efficacy of this approach for the induction and maintenance of response and remission in Crohn's disease...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28138445/cardiac-tamponade-as-a-presenting-manifestation-of-infliximab-induced-lupus-in-patient-treated-for-crohn-s-disease
#17
Maliha Naseer, Zain Kulairi, Michael Kam
Crohn's disease is characterized by inflammation of the mucosal lining of the gastrointestinal tract. Infliximab is a tumor necrosis factor-α inhibitor that has been associated with increased remission and decreased disease flare-ups. Biological agents such as infliximab have been associated with adverse events. We present a rare case of cardiac tamponade caused by infliximab treatment for Crohn's disease in a 30-year-old female. She was treated with emergent pericardial window and drainage of pericardial fluid...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/28137597/molecular-imaging-of-mucosal-%C3%AE-4%C3%AE-7-integrin-expression-with-the-fluorescent-anti-adhesion-antibody-vedolizumab-in-crohn-s-disease
#18
Timo Rath, Christian Bojarski, Markus F Neurath, Raja Atreya
No abstract text is available yet for this article.
January 27, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28112566/costs-of-providing-infusion-therapy-for-patients-with-inflammatory-bowel-disease-in-a-hospital-based-infusion-center-setting
#19
Anita Afzali, Kristine Ogden, Michael L Friedman, Jingdong Chao, Anthony Wang
Aims Inflammatory bowel disease (IBD) (e.g., ulcerative colitis [UC] and Crohn's disease [CD]) severely impacts patient quality of life. Moderate to severe disease is often treated with biologics requiring infusion therapy, adding incremental costs beyond drug costs. This study evaluates US hospital-based infusion services costs for treatment of UC or CD patients receiving infliximab or vedolizumab therapy. Materials and methods A model was developed, estimating annual costs of providing monitored infusions using activity-based costing framework approach...
January 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28070861/efficacy-and-safety-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-patients-stratified-by-age
#20
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch
INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. METHODS: Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years...
January 9, 2017: Advances in Therapy
keyword
keyword
45192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"